🚀 VC round data is live in beta, check it out!
CellaVision Valuation Multiples
Discover revenue and EBITDA valuation multiples for CellaVision and similar public comparables like OrthoPediatrics, IVF hartmann, Coltene, Cerus and more.
CellaVision Overview
About CellaVision
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.
Founded
1994
HQ
Employees
236
Website
Financials (LTM)
EV
$403M
CellaVision Financials
CellaVision reported last 12-month revenue of $86M and EBITDA of $27M.
In the same LTM period, CellaVision generated $59M in gross profit, $27M in EBITDA, and $18M in net income.
Revenue (LTM)
CellaVision P&L
In the most recent fiscal year, CellaVision reported revenue of $84M and EBITDA of $27M.
CellaVision expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $86M | XXX | $84M | XXX | XXX | XXX |
| Gross Profit | $59M | XXX | $57M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $27M | XXX | $27M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 32% | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $18M | XXX | $17M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 20% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
CellaVision Stock Performance
CellaVision has current market cap of $421M, and enterprise value of $403M.
Market Cap Evolution
CellaVision's stock price is $17.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $403M | $421M | 0.3% | XXX | XXX | XXX | $0.72 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCellaVision Valuation Multiples
CellaVision trades at 4.7x EV/Revenue multiple, and 14.7x EV/EBITDA.
EV / Revenue (LTM)
CellaVision Financial Valuation Multiples
As of April 19, 2026, CellaVision has market cap of $421M and EV of $403M.
Equity research analysts estimate CellaVision's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CellaVision has a P/E ratio of 23.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $421M | XXX | $421M | XXX | XXX | XXX |
| EV (current) | $403M | XXX | $403M | XXX | XXX | XXX |
| EV/Revenue | 4.7x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | 14.7x | XXX | 15.1x | XXX | XXX | XXX |
| EV/EBIT | 17.6x | XXX | 18.0x | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | 7.1x | XXX | XXX | XXX |
| P/E | 23.9x | XXX | 24.6x | XXX | XXX | XXX |
| EV/FCF | 31.7x | XXX | 31.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CellaVision Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
CellaVision Margins & Growth Rates
CellaVision's revenue in the last 12 month grew by 9%.
CellaVision's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
CellaVision's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CellaVision's rule of X is 55% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
CellaVision Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 15% | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
CellaVision Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CellaVision | XXX | XXX | XXX | XXX | XXX | XXX |
| OrthoPediatrics | XXX | XXX | XXX | XXX | XXX | XXX |
| IVF hartmann | XXX | XXX | XXX | XXX | XXX | XXX |
| Coltene | XXX | XXX | XXX | XXX | XXX | XXX |
| Cerus | XXX | XXX | XXX | XXX | XXX | XXX |
| AngioDynamics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CellaVision M&A Activity
CellaVision acquired XXX companies to date.
Last acquisition by CellaVision was on XXXXXXXX, XXXXX. CellaVision acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by CellaVision
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCellaVision Investment Activity
CellaVision invested in XXX companies to date.
CellaVision made its latest investment on XXXXXXXX, XXXXX. CellaVision invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by CellaVision
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CellaVision
| When was CellaVision founded? | CellaVision was founded in 1994. |
| Where is CellaVision headquartered? | CellaVision is headquartered in Sweden. |
| How many employees does CellaVision have? | As of today, CellaVision has over 236 employees. |
| Who is the CEO of CellaVision? | CellaVision's CEO is Simon Ostergaard. |
| Is CellaVision publicly listed? | Yes, CellaVision is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of CellaVision? | CellaVision trades under CEVI ticker. |
| When did CellaVision go public? | CellaVision went public in 2007. |
| Who are competitors of CellaVision? | CellaVision main competitors are OrthoPediatrics, IVF hartmann, Coltene, Cerus. |
| What is the current market cap of CellaVision? | CellaVision's current market cap is $421M. |
| What is the current revenue of CellaVision? | CellaVision's last 12 months revenue is $86M. |
| What is the current revenue growth of CellaVision? | CellaVision revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of CellaVision? | Current revenue multiple of CellaVision is 4.7x. |
| Is CellaVision profitable? | Yes, CellaVision is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CellaVision? | CellaVision's last 12 months EBITDA is $27M. |
| What is CellaVision's EBITDA margin? | CellaVision's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of CellaVision? | Current EBITDA multiple of CellaVision is 14.7x. |
| What is the current FCF of CellaVision? | CellaVision's last 12 months FCF is $13M. |
| What is CellaVision's FCF margin? | CellaVision's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of CellaVision? | Current FCF multiple of CellaVision is 31.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.